Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial

JAMA Network Open

Volumn 3, Issue 423, 2020, Pages E208857-

  Borba, Mayla Gabriela Silva ^a,b   Val, Fernando Fonseca Almeida ^a,b   Sampaio, Vanderson Souza ^a,b,c   Alexandre, Marcia Almeida Araújo ^a   Melo, Gisely Cardoso ^a,b   Brito, Marcelo ^a,b   Mourão, Maria Paula Gomes ^a,b   Brito Sousa, José Diego ^a,b   Baía Da Silva, Djane ^a,b   Guerra, Marcus Vinitius Farias ^a   Hajjar, Ludhmila Abrahão ^d   Pinto, Rosemary Costa ^c   Balieiro, Antonio Alcirley Silva ^e   Pacheco, Antônio Guilherme Fonseca ^f   Santos, James Dean Oliveira ^g   Naveca, Felipe Gomes ^e   Xavier, Mariana Simão ^f   Siqueira, André Machado ^f   Schwarzbold, Alexandre ^h   Croda, Júlio ^f,i   Nogueira, Maurício Lacerda ^j   Romero, Gustavo Adolfo Sierra ^k   Bassat, Quique ^l,m,n,o,p   Fontes, Cor Jesus ^q   Albuquerque, Bernardino Cláudio ^g   Daniel Ribeiro, Cláudio Tadeu ^f   Monteiro, Wuelton Marcelo ^a,b   Lacerda, Marcus Vinícius Guimarães ^a,b,e   more..

^a FUNDAÇÃO DE MEDICINA TROPICAL DR HEITOR VIEIRA DOURADO   (Brazil)

^b UNIVERSIDADE DO ESTADO DO AMAZONAS   (Brazil)

^c Fundação de Vigilância em Saúde do Amazonas Dra Rosemary Costa Pinto   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e INSTITUTO LEÔNIDAS E MARIA DEANE   (Brazil)

^f INSTITUTO OSWALDO CRUZ   (Brazil)

^g FEDERAL UNIVERSITY OF AMAZONAS   (Brazil)

^h FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

ⁱ FEDERAL UNIVERSITY OF MATO GROSSO DO SUL   (Brazil)

^j FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

^k UNIVERSITY OF BRASILIA   (Brazil)

^l CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^m Manhiça Health Research Center   (Mozambique)

ⁿ INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^o UNIVERSITY OF BARCELONA   (Spain)

^p CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^q FEDERAL UNIVERSITY OF MATO GROSSO   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; CHLOROQUINE; OSELTAMIVIR;

ADULT; AGED; BETACORONAVIRUS; BRAZIL; CLINICAL TRIAL; CONTROLLED STUDY; CORONAVIRUS INFECTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; EPIDEMIC; FEMALE; HUMAN; MALE; MIDDLE AGED; PANDEMIC; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TERTIARY CARE CENTER; VIRUS PNEUMONIA;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; AZITHROMYCIN; BETACORONAVIRUS; BRAZIL; CHLOROQUINE; CORONAVIRUS INFECTIONS; DISEASE OUTBREAKS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OSELTAMIVIR; PANDEMICS; PNEUMONIA, VIRAL; TERTIARY CARE CENTERS;

EID: 85084030506     PISSN: None     EISSN: 25743805     Source Type: Journal    
DOI: 10.1001/jamanetworkopen.2020.8857     Document Type: Article

References (32)

1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020; 395 (10223): 470-473. doi: 10.1016/S0140-6736(20)30185-9 31986257
2. Holshue ML, DeBolt C, Lindquist S,; Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020; 382 (10): 929-936. doi: 10.1056/nejmoa2001191 32004427
3. Rodriguez-Morales AJ, Gallego V, Escalera-Antezana JP, COVID-19 in Latin America: the implications of the first confirmed case in Brazil. Travel Med Infect Dis. 2020: 101613. doi: 10.1016/j.tmaid.2020.101613 32126292
4. Ling Z, Xu X, Gan Q, Asymptomatic SARS-CoV-2 infected patients with persistent negative CT findings. Eur J Radiol. 2020; 126: 108956. doi: 10.1016/j.ejrad.2020.108956 32199142
5. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. 2020; 24 (1): 108. doi: 10.1186/s13054-020-2833-7 32188484
6. Yang X, Yu Y, Xu J, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020: S2213-2600(20)30079-5. doi: 10.1016/S2213-2600(20)30079-5 32105632
7. Zhou F, Yu T, Du R, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10229): 1054-1062. doi: 10.1016/s0140-6736(20)30566-3 32171076
8. Vincent MJ, Bergeron E, Benjannet S, Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005; 2: 69. doi: 10.1186/1743-422X-2-69 16115318
9. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004; 323 (1): 264-268. doi: 10.1016/j.bbrc.2004.08.085 15351731
10. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43 (3): 185-188. 32164085
11. Wang M, Cao R, Zhang L, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30 (3): 269-271. doi: 10.1038/s41422-020-0282-0 32020029
12. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14 (1): 72-73. doi: 10.5582/bst.2020.01047 32074550
13. Gautret P, Lagier J-C, Parola P, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020: 105949. doi: 10.1016/j.ijantimicag.2020.105949 32205204
14. Lim HS, Im JS, Cho JY, Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother. 2009; 53 (4): 1468-1475. doi: 10.1128/AAC.00339-08 19188392
15. Science Direct. Chloroquine retinopathy. Accessed March 20, 2020. https://www.sciencedirect.com/topics/medicine-and-dentistry/chloroquine-retinopathy
16. Kazi MS, Saurabh K, Rishi P, Rishi E. Delayed onset chloroquine retinopathy presenting 10 years after long-term usage of chloroquine. Middle East Afr J Ophthalmol. 2013; 20 (1): 89-91. doi: 10.4103/0974-9233.106404 23580861
17. Mavrikakis I, Sfikakis PP, Mavrikakis E, The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003; 110 (7): 1321-1326. doi: 10.1016/S0161-6420(03)00409-3 12867385
18. Silva JA, Silva MB, Skare TL. Chloroquine and QTc interval. Clin Exp Rheumatol. 2007; 25 (5): 795. 18078640
19. Inglot AD. Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs. J Gen Virol. 1969; 4 (2): 203-214. doi: 10.1099/0022-1317-4-2-203 4306296
20. Miller DK, Lenard J. Antihistaminics, local anesthetics, and other amines as antiviral agents. Proc Natl Acad Sci U S A. 1981; 78 (6): 3605-3609. doi: 10.1073/pnas.78.6.3605 6115382
21. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010; 8: 18. doi: 10.1186/1741-7015-8-18 20334633
22. Lu X, Zhang L, Du H,; Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 infection in children. N Engl J Med. 2020. Published online March 18, 2020. doi: 10.1056/NEJMc2005073 32187458
23. Chen T, Wu D, Chen H, Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020; 368: m1091. doi: 10.1136/bmj.m1091 32217556
24. Grasselli G, Zangrillo A, Zanella A,; COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020. Published April 6, 2020. doi: 10.1001/jama.2020.5394 32250385
25. Karasic TB, O'Hara MH, Loaiza-Bonilla A, Effect of gemcitabine and nab-paclitaxel with or without hydroxychloroquine on patients with advanced pancreatic cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2019; 5 (7): 993-998. doi: 10.1001/jamaoncol.2019.0684 31120501
26. Rangwala R, Leone R, Chang YC, Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy. 2014; 10 (8): 1369-1379. doi: 10.4161/auto.29118 24991839
27. Nti AA, Serrano LW, Sandhu HS, Frequent subclinical macular changes in combined BRAF/MEK inhibition with high-dose hydroxychloroquine as treatment for advanced metastatic BRAF mutant melanoma: preliminary results from a phase i/ii clinical treatment trial. Retina. 2019; 39 (3): 502-513. doi: 10.1097/IAE.0000000000002027 29324592
28. US Centers for Disease Control and Prevention. CDC 2019-novel coronavirus (2019-nCoV): real-time RT-PCR diagnostic panel. Updated March 15, 2020. Accessed April 21, 2020. https://www.fda.gov/media/134922/download
29. ClinicalTrials.gov. Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease (ORCHID). Accessed April 21, 2020. https://clinicaltrials.gov/ct2/show/NCT04332991?term=NCT04332991&draw=2&rank=1
30. ClinicalTrials.gov. Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection (CloroCOVID19II). Accessed April 21, 2020. https://clinicaltrials.gov/ct2/show/NCT04342650?term=NCT04342650&draw=2&rank=1
31. Chorin E, Dai M, Shulman E, The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin. Published April 3, 2020. Accessed April 20, 2020. https://www.medrxiv.org/content/10.1101/2020.04.02.20047050v1
32. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004; 323 (1): 264-268. doi: 10.1016/j.bbrc.2004.08.085 15351731